- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01639794
Vesitirim™ in Men Postmarketing Observational Study (VIM)
An Irish Observational Study to Evaluate LUTS Storage Symptom Improvement in Men Being Treated With Vesitirim™ (Solifenacin)
This is an observational study which will look at the improvement in Lower Urinary Tract Symptoms (LUTS) in Irish men being treated with Vesitirim™ (solifenacin).
Vesitirim™ is a competitive specific muscarinic receptor antagonist and has been used extensively for the treatment of OAB (Over Active Bladder) in women and has shown significant impact on urgency, frequency and incontinence in females. It is also indicated for the symptomatic treatment of urgency incontinence and/or increased urinary frequency and urgency in men. The purpose of this study is to evaluate LUTS storage symptom improvement in men with non neurogenic LUTS who have been prescribed Vesitirim™.
The effect of Vesitirim (solifenacin) treatment on bothersome symptoms improvement will be measured using Over Active Bladder-q Short Form (OAB-qSF) and the Perception of Treatment Satisfaction (TS-VAS). The study will also help define some of the characteristics of the male population in Ireland who are treated with Vesitirim™ (solifenacin) as well as evaluating the effect of Vesitirim™ monotherapy or combination therapy on storage symptoms improvement (urgency, frequency and urge incontinence) using a bladder diary and IPSS (International Prostate Symptom Score). The study will also evaluate the effect of Vesitirim™ monotherapy or combination therapy on nocturia using IPSS. The impact of LUTS on quality of life will also be assessed. Data will also be collected regarding adverse drug reactions.
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a post marketing, non-interventional study (NIS) of patients who are to be treated with Vesitirim™. The decision whether or not to treat with Vesitirim™ will be made by the treating physician prior to the entry of the patient into the study. The patient will be informed of the study and written consent will be obtained prior to screening and determination of eligibility.
No study drug will be supplied as part of this study.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Cork, Ireland
- Site 2 - Mercy University Hospital
-
Dublin, Ireland, 24
- Site: 4 - Tallaght Hospital
-
Dublin, Ireland, 8
- Site: 1 - St James Hopsital
-
Dublin, Ireland, 9
- Site: 5 - Beaumont Hospital
-
Sligo, Ireland
- Site: 3 - Sligo General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diagnosis of non-neurogenic Lower Urinary Tract Symptoms (LUTS) with bothersome storage disorder defined as urgency, and/or frequency and/or Urge Urinary Incontinence (UUI) at the discretion of the Investigator
- Eligible to start Vesitirim™ 5 or 10mg according to SmPC (Summary of Product Characteristics )
Exclusion Criteria:
- History of stress incontinence
- Active urinary tract infection (confirmed by positive urine analysis)
- Symptoms suggestive of severe Bladder Outlet Obstruction (BOO) defined as Qmax<10ml/sc and/or PVR>150ml
- History of known hypersensitivity to solifenacin succinate, oxybutynin hydrochloride, other anti-cholinergics or lactose, to any component of the dosage form or any other allergy, which, in the opinion of the Investigator contraindicates their participation
- Uncontrolled Diabetes Mellitus
- History of drug and/or alcohol abuse at the time of enrolment
- History of acute urinary retention, severe gastrointestinal obstruction (including paralytic ileus or intestinal atony or toxic megacolon or severe ulcerative colitis), myasthenia gravis, uncontrolled narrow glaucoma or swallow anterior chamber or deemed to be at risk of these conditions
- Undergoing haemodialysis or has severe renal impairment or moderate hepatic impairment and who are on treatment with a potent CYP3A4 inhibitor
- History of urogenital tumours which in the opinion of the Investigator precludes their participation in the study
- Likely to participate in another study during study period of 12 weeks from study entry
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Male patients with non-neurogenic LUTS taking VESITRIM
Male patients diagnosed with non-neurogenic Lower Urinary Tract Symptoms (LUTS) with bothersome storage disorder defined as urgency, and/or frequency and/or Urgency Urinary Incontinence (UUI)
|
Oral
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline to visit 2 in Over Active Bladder questionnaire Short Form (OAB-q SF) score
Time Frame: Baseline and 12 weeks
|
Baseline and 12 weeks
|
Change from baseline to visit 2 in patient assessment of treatment satisfaction (TS-VAS)
Time Frame: Baseline and 12 weeks
|
Baseline and 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline to visit 2 in voiding function assessed by Qmax and PVR
Time Frame: Baseline and 12 weeks
|
Baseline and 12 weeks
|
Change from baseline to visit 2 in patient perception of voiding symptoms assessed by: IPSS scores and number of urge incontinence (UUI) episodes per week
Time Frame: Baseline and 12 weeks
|
Baseline and 12 weeks
|
Change from baseline to visit 2 in storage symptoms assessed by micturition diary; number of urgency episodes per 24 hours; number of micturition per 24 hours and number of nocturia episodes per 24 hours
Time Frame: Baseline and 12 weeks
|
Baseline and 12 weeks
|
Change from baseline to visit 2 in quality of life assessed by IPSS score
Time Frame: Baseline and 12 weeks
|
Baseline and 12 weeks
|
Adverse drug reactions- incidence of acute urinary retention and urinary tract infection
Time Frame: Baseline and 12 weeks
|
Baseline and 12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Medical Director, Astellas Pharma Co. Ltd (APCL)
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urologic Diseases
- Urinary Bladder Diseases
- Urological Manifestations
- Urinary Bladder, Overactive
- Lower Urinary Tract Symptoms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Muscarinic Antagonists
- Cholinergic Antagonists
- Cholinergic Agents
- Urological Agents
- Solifenacin Succinate
Other Study ID Numbers
- VES-IE-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overactive Bladder (OAB)
-
Stimvia s.r.o.CompletedOveractive Bladder (OAB) | Failed Any OAB PharmacotherapyCzechia
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedOveractive Bladder (OAB)United States, Canada, Germany, Korea, Republic of, Spain, Turkey, Taiwan, Italy, Slovakia, Denmark, South Africa, United Kingdom, Mexico, Sweden, Norway
-
Medstar Health Research InstituteColumbia University; University of Michigan; University of New Mexico; Methodist...Terminated
-
Astellas Pharma Global Development, Inc.CompletedOveractive Bladder (OAB)United States, Canada
-
Astellas Pharma Singapore Pte. Ltd.CompletedOveractive Bladder (OAB)Korea, Republic of, Australia
-
Jeil Pharmaceutical Co., Ltd.CompletedOveractive Bladder(OAB)Korea, Republic of
-
NovartisProcter and GambleCompletedOveractive Bladder (OAB)United States
-
Astellas Pharma Singapore Pte. Ltd.CompletedOveractive Bladder (OAB)Korea, Republic of, Australia
-
National and Kapodistrian University of AthensCompletedOveractive Bladder (OAB)Greece
Clinical Trials on Vesitirim™ (Solifenacin)
-
Astellas Pharma Europe B.V.CompletedPediatric | Neurogenic Detrusor OveractivityUnited States, Belgium, Korea, Republic of, Philippines, Poland, United Kingdom
-
Astellas Pharma IncCompletedHealthy Volunteers | Pharmacokinetics of Solifenacin Succinate | Bioavailability of Solifenacin SuccinateUnited States
-
Astellas Pharma IncCompletedUrinary Bladder, OveractiveSweden, United Kingdom, Belgium, Denmark
-
Hanmi Pharmaceutical Company LimitedCompleted
-
Astellas Pharma Europe B.V.CompletedUrinary Bladder, OveractiveBelgium, United States, Brazil, Canada, Denmark, Former Serbia and Montenegro, Korea, Republic of, Mexico, Norway, Philippines, Poland, South Africa, Sweden, Turkey, Ukraine, United Kingdom
-
Center Eugene MarquisTerminated
-
Lahey ClinicAstellas Pharma US, Inc.TerminatedOveractive BladderUnited States
-
National Taiwan University HospitalUnknownOveractive Bladder SyndromeTaiwan
-
Astellas Pharma IncCompletedHealthy Volunteers | Pharmacokinetics of Solifenacin SuccinateUnited States
-
KYU-SUNG LEEAstellas Pharma Korea, Inc.CompletedOveractive BladderKorea, Republic of